title: Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease.
abstract: BACKGROUND
  Fatigue affects 40% to 50% of all PD patients and is a leading cause of disability, with no clearly established or efficacious established treatments.
  
  
  METHODS
  In this double-blinded, placebo-controlled, pilot trial, we investigated whether rasagiline improved fatigue among PD patients. Subjects were randomized to 1 mg daily of rasagiline or placebo for 12 weeks. The primary endpoint was a change in the Modified Fatigue Impact Scale from baseline to week 12.
  
  
  RESULTS
  Thirty PD subjects (16 men), with Modified Fatigue Impact Scale baseline score of 67 ± 15, were randomized (16 to rasagiline vs. 14 to placebo). Significant improvement was noted in the mean Modified Fatigue Impact Scale score of the rasagiline group (12 points) as compared to placebo (8.5 points) from baseline to week 12 (P = 0.003).
  
  
  CONCLUSIONS
  In this pilot study, rasagiline at a dose of 1 mg per day improved fatigue. Larger randomized studies are needed to confirm this finding.
authors.affiliation: Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Thien Thien
authors.initials: TT
authors.lastname: Lim
authors.affiliation: Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Benzi M
authors.initials: BM
authors.lastname: Kluger
authors.affiliation: University of Florida, Gainesville, Florida, USA.
authors.forename: Ramon L
authors.initials: RL
authors.lastname: Rodriguez
authors.affiliation: University of Florida, Gainesville, Florida, USA.
authors.forename: Irene A
authors.initials: IA
authors.lastname: Malaty
authors.affiliation: Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Rafael
authors.initials: R
authors.lastname: Palacio
authors.affiliation: Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Oluwadamilola O
authors.initials: OO
authors.lastname: Ojo
authors.affiliation: Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Shnehal
authors.initials: S
authors.lastname: Patel
authors.affiliation: Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Yogesh
authors.initials: Y
authors.lastname: Gujrati
authors.affiliation: Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Nutter
authors.affiliation: University of Florida, Gainesville, Florida, USA.
authors.forename: Camille
authors.initials: C
authors.lastname: Swartz
authors.affiliation: University of Colorado, Aurora, Coloradio, USA.
authors.forename: Carol
authors.initials: C
authors.lastname: Hennessy
authors.affiliation: Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Hubert H
authors.initials: HH
authors.lastname: Fernandez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005221:Fatigue / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications*; D010865:Pilot Projects; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D007189:Indans; D018696:Neuroprotective Agents; C031967:rasagiline
keywords: Parkinson's disease; fatigue; rasagiline